文献速递肝病消化道肿瘤与早癌

全基因组关联研究发现TLL1变异与丙型肝炎病毒感染根除后肝细胞癌发生相关

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
PubMed 文献 · Gastroenterology · 2017-02-03

研究对日本457例干扰素治疗获得持续病毒学应答的慢性丙型肝炎患者行全基因组关联分析,并在486例独立人群中复制,发现TLL1内含子SNP rs17047200与肝细胞癌发生显著相关(合并比值比2.37,P=2.66×10⁻⁸),多因素分析显示rs17047200 AT/TT为独立危险因素(风险比1.78,P=.008)。

要点

  • TLL1内含子SNP rs17047200与丙肝持续病毒学应答后肝细胞癌发生在全基因组水平显著相关(比值比2.37,P=2.66×10⁻⁸)。
  • rs17047200 AT/TT是肝细胞癌发生的独立危险因素(风险比1.78,P=.008),联合其他因素可构建预测模型。
  • TLL1 mRNA在肝星状细胞活化、 rodent肝纤维化模型及人肝纤维化组织中升高,rs17047200 AT/TT者短变体表达更高。

核心结论

  • 全基因组关联研究发现TLL1内含子SNP rs17047200与慢性丙型肝炎治疗获得持续病毒学应答后肝细胞癌发生相关。
  • 作者提出该SNP可能影响TLL1 mRNA剪接,产生高催化活性短变体,加速肝纤维化与癌变。
  • 作者认为TLL1 SNP检测可能用于识别丙肝治疗后持续病毒学应答患者的肝细胞癌风险。

研究设计与样本

  • 全基因组关联研究纳入日本2007年至2015年干扰素治疗获得持续病毒学应答的慢性丙型肝炎患者457例,并在486例独立日本人群中复制79个候选单核苷酸多态性。
  • 研究终点为肝细胞癌诊断或确认无肝细胞癌,全基因组关联队列随访至2014年12月,复制队列随访至2016年1月。
  • 分析人肝星状细胞、缺乏胆碱L-氨基酸定义饮食所致脂肪性肝炎大鼠、四氯化碳所致肝损伤小鼠模型及不同纤维化分期或肿瘤的慢性丙型肝炎患者肝组织中候选基因变异表达水平。

主要发现

  • 全基因组关联分析与复制研究合并后,染色体4上TLL1内含子SNP rs17047200与肝细胞癌发生呈全基因组水平显著关联(比值比2.37,P=2.66×10⁻⁸)。
  • 多因素分析显示rs17047200 AT/TT为肝细胞癌独立危险因素(风险比1.78,P=.008),男性、年龄较大、白蛋白较低、肝纤维化晚期、糖尿病及治疗后甲胎蛋白较高亦为独立因素。
  • 结合rs17047200基因型与其他因素构建了轻度或晚期肝纤维化患者肝细胞癌发生预测模型。
  • 人肝星状细胞活化时TLL1信使RNA水平升高,rodent肝纤维化模型及纤维化进展患者肝组织中Tll1/TLL1信使RNA水平较对照升高。
  • rs17047200 AT/TT患者TLL1短变体(包括同种型2)基因表达水平较高。

临床怎么用

  • 作者认为TLL1 SNP检测可能用于识别丙型肝炎病毒感染治疗后持续病毒学应答患者的肝细胞癌风险。
  • 作者提出需进一步研究rs17047200如何影响TLL1 mRNA水平、剪接和翻译,以及该变异在其他肝细胞癌患者中的患病率。

局限性

  • 作者提出需进一步研究rs17047200如何影响TLL1 mRNA水平、剪接和翻译,以及该变异在其他肝细胞癌患者中的患病率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is still a risk for hepatocellular carcinoma (HCC) development after eradication of hepatitis C virus (HCV) infection with antiviral agents. We investigated genetic factors associated with the development of HCC in patients with a sustained virologic response (SVR) to treatment for chronic HCV infection. METHODS: We obtained genomic DNA from 457 patients in Japan with a SVR to interferon-based treatment for chronic HCV infection from 2007 through 2015. We conducted a genome-wide association study (GWAS), followed by a replication analysis of 79 candidate single nucleotide polymorphisms (SNPs) in an independent set of 486 patients in Japan. The study end point was HCC diagnosis or confirmation of lack of HCC (at follow-up examinations until December 2014 in the GWAS cohort, and until January 2016 in the replication cohort). We collected clinical and laboratory data from all patients. We analyzed expression levels of candidate gene variants in human hepatic stellate cells, rats with steatohepatitis caused by a choline-deficient L-amino acid-defined diet, and a mouse model of liver injury caused by administration of carbon tetrachloride. We also analyzed expression levels in liver tissues of patients with chronic HCV infection with different stages of fibrosis or tumors vs patients without HCV infection (controls). RESULTS: We found a strong association between the SNP rs17047200, located within the intron of the tolloid like 1 gene (TLL1) on chromosome 4, and development of HCC; there was a genome-wide level of significance when the results of the GWAS and replication study were combined (odds ratio, 2.37; P = 2.66 × 10-8). Multivariate analysis showed rs17047200 AT/TT to be an independent risk factor for HCC (hazard ratio, 1.78; P = .008), along with male sex, older age, lower level of albumin, advanced stage of hepatic fibrosis, presence of diabetes, and higher post-treatment level of α-fetoprotein. Combining the rs17047200 genotype with other factors, we developed prediction models for HCC development in patients with mild or advanced hepatic fibrosis. Levels of TLL1 messenger RNA (mRNA) in human hepatic stellate cells increased with activation. Levels of Tll1 mRNA increased in liver tissues of rodents with hepatic fibrogenesis compared with controls. Levels of TLL1 mRNA increased in liver tissues of patients with progression of fibrosis. Gene expression levels of TLL1 short variants, including isoform 2, were higher in patients with rs17047200 AT/TT. CONCLUSIONS: In a GWAS, we identified the association between the SNP rs17047200, within the intron of TLL1, and development of HCC in patients who achieved an SVR to treatment for chronic HCV infection. We found levels of Tll1/TLL1 mRNA to be increased in rodent models of liver injury and liver tissues of patients with fibrosis, compared with controls. We propose that this SNP might affect splicing of TLL1 mRNA, yielding short variants with high catalytic activity that accelerates hepatic fibrogenesis and carcinogenesis. Further studies are needed to determine how rs17047200 affects TLL1 mRNA levels, splicing, and translation, as well as the prevalence of this variant among other patients with HCC. Tests for the TLL1 SNP might be used to identify patients at risk for HCC after an SVR to treatment of HCV infection.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Matsuura K, Sawai H, Ikeo K, et al. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. 2017. PMID: 28163062. doi:10.1053/j.gastro.2017.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。